Trial · NCT03164564
Adverse events1,380
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 1,380
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eustachian tube obstruction | Ear and labyrinth disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 0 | 1,614 | 0 |
| other | Eustachian tube obstruction | Ear and labyrinth disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 1 | 1,610 | 1 |
| other | Excessive cerumen production | Ear and labyrinth disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 1 | 1,614 | 1 |
| other | Excessive cerumen production | Ear and labyrinth disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 0 | 1,610 | 0 |
| other | Otorrhoea | Ear and labyrinth disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 0 | 1,614 | 0 |
| other | Otorrhoea | Ear and labyrinth disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 1 | 1,610 | 1 |
| other | Tympanic membrane perforation | Ear and labyrinth disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 1 | 1,614 | 1 |
| other | Tympanic membrane perforation | Ear and labyrinth disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 0 | 1,610 | 0 |
| other | Any Event in SOC | Endocrine disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 1 | 1,614 | 1 |
| other | Any Event in SOC | Endocrine disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 1 | 1,610 | 1 |
| other | Goitre | Endocrine disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 1 | 1,614 | 1 |
| other | Goitre | Endocrine disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 1 | 1,610 | 1 |
| other | Any Event in SOC | Eye disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 47 | 1,614 | 59 |
| other | Any Event in SOC | Eye disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 38 | 1,610 | 42 |
| other | Asthenopia | Eye disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 1 | 1,614 | 1 |
| other | Asthenopia | Eye disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 0 | 1,610 | 0 |
| other | Blepharitis | Eye disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 1 | 1,614 | 1 |
| other | Blepharitis | Eye disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 0 | 1,610 | 0 |
| other | Blindness unilateral | Eye disorders | Arm A: CAB + Placebo TDF/FTC + CAB LA | 0 | 1,614 | 0 |
| other | Blindness unilateral | Eye disorders | Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA | 1 | 1,610 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03164564/events?page=3